Sustained Delivery of Rifampicin Nanoformulation Administration Intravitreally Into Rabbit Eyes for Ocular Tuberculosis
Diagnosis and treatment of ocular tuberculosis is very challenging. It poses a significant and potential management dilemma after diagnosis as a primary, active, or secondary infection. The higher amounts of orally administered antitubercular drugs are needed to achieve the therapeutic concentration...
Gespeichert in:
Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2024-07, Vol.16 (7), p.e65368 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 7 |
container_start_page | e65368 |
container_title | Curēus (Palo Alto, CA) |
container_volume | 16 |
creator | Yadav, Rohitash Tiwari, Chakrmani Kumar, Vinod Pandey, Avaneesh Kondel, Ritika Shafiq, Nushrat |
description | Diagnosis and treatment of ocular tuberculosis is very challenging. It poses a significant and potential management dilemma after diagnosis as a primary, active, or secondary infection. The higher amounts of orally administered antitubercular drugs are needed to achieve the therapeutic concentration in the eye, which may lead to a higher risk of side effects. However, the intravitreal administration of drugs is not practiced because of the frequent administration of the injections.
This study was carried out to develop, optimize, and characterize rifampicin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles to make them sustained release followed by the direct administration of plain rifampicin and rifampicin nano-formulations in the vitreous of rabbit eyes. Both groups were comparatively assessed for the sustained delivery of the two preparations in the vitreous and their systemic toxicity.
The characteristics of rifampicin-loaded nanoparticles were 786 nm in size with narrow size distribution along with a zeta potential of -12 mV. The drug encapsulation efficiency and loading capacity were 67.68% w/w and 42.28% w/w, respectively. The four New Zealand white rabbits were divided into two groups and given plain rifampicin (50µl volume) and PLGA nanoformulations of rifampicin (50µl volume) in each eye. In vivo, rifampicin-loaded PLGA nanoparticles produced sustained release of rifampicin for a week, even obtaining the 0.51 µg/ml levels on the seventh day in vitreous against negligible levels after one day for free rifampicin. The Cmax levels for free Rifampicin and Rifampicin nanoparticles were 0.44 µg/ml and 1.86 µg/ml, respectively.
In this experimental proof-of-concept study, we have found that rifampicin-loaded PLGA nanoparticles released rifampicin in a sustained manner for up to seven days compared to free drugs only for one day into the vitreous. The intravitreal-administered drug did not reach systemic circulation. |
doi_str_mv | 10.7759/cureus.65368 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3097154917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3099255219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c244t-58f2319b1e7445bdc71e089154d4200c3ddcc56b547d8a1862f43c86e933da823</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMoVrQ71xJw48LWPCfJUnyDKPhYD5kkA5GZSU0mSv-9qa0iru65l-8cLhwADjGaC8HVmcnR5TSvOK3kFtgjuJIziSXb_qMnYJrSG0III0GQQLtgQlW5C8b3wOdzTqP2g7Pw0nX-w8UlDC188q3uF974AT7oIbQh9rnTow8DPLe9H3wa43q9G4r68GN0uuuWqzXAJ900foRXS5dgscJHU8wRvuTGxSJD8ukA7LS6S266mfvg9frq5eJ2dv94c3dxfj8zhLFxxmVLKFYNdoIx3lgjsENSYc4sIwgZaq0xvGo4E1ZqLCvSMmpk5RSlVktC98HJOncRw3t2aax7n4zrOj24kFNNkRIlTWFR0ON_6FvIcSjfrShFOCdYFep0TZkYUoqurRfR9zoua4zqVSf1upP6u5OCH21Cc9M7-wv_NEC_AMeficA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3099255219</pqid></control><display><type>article</type><title>Sustained Delivery of Rifampicin Nanoformulation Administration Intravitreally Into Rabbit Eyes for Ocular Tuberculosis</title><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Yadav, Rohitash ; Tiwari, Chakrmani ; Kumar, Vinod ; Pandey, Avaneesh ; Kondel, Ritika ; Shafiq, Nushrat</creator><creatorcontrib>Yadav, Rohitash ; Tiwari, Chakrmani ; Kumar, Vinod ; Pandey, Avaneesh ; Kondel, Ritika ; Shafiq, Nushrat</creatorcontrib><description>Diagnosis and treatment of ocular tuberculosis is very challenging. It poses a significant and potential management dilemma after diagnosis as a primary, active, or secondary infection. The higher amounts of orally administered antitubercular drugs are needed to achieve the therapeutic concentration in the eye, which may lead to a higher risk of side effects. However, the intravitreal administration of drugs is not practiced because of the frequent administration of the injections.
This study was carried out to develop, optimize, and characterize rifampicin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles to make them sustained release followed by the direct administration of plain rifampicin and rifampicin nano-formulations in the vitreous of rabbit eyes. Both groups were comparatively assessed for the sustained delivery of the two preparations in the vitreous and their systemic toxicity.
The characteristics of rifampicin-loaded nanoparticles were 786 nm in size with narrow size distribution along with a zeta potential of -12 mV. The drug encapsulation efficiency and loading capacity were 67.68% w/w and 42.28% w/w, respectively. The four New Zealand white rabbits were divided into two groups and given plain rifampicin (50µl volume) and PLGA nanoformulations of rifampicin (50µl volume) in each eye. In vivo, rifampicin-loaded PLGA nanoparticles produced sustained release of rifampicin for a week, even obtaining the 0.51 µg/ml levels on the seventh day in vitreous against negligible levels after one day for free rifampicin. The Cmax levels for free Rifampicin and Rifampicin nanoparticles were 0.44 µg/ml and 1.86 µg/ml, respectively.
In this experimental proof-of-concept study, we have found that rifampicin-loaded PLGA nanoparticles released rifampicin in a sustained manner for up to seven days compared to free drugs only for one day into the vitreous. The intravitreal-administered drug did not reach systemic circulation.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.65368</identifier><identifier>PMID: 39184745</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Animals ; Chromatography ; Drug delivery systems ; Drug dosages ; Ketamine ; Nanoparticles ; Particle size ; Plasma ; Rabbits ; Tuberculosis</subject><ispartof>Curēus (Palo Alto, CA), 2024-07, Vol.16 (7), p.e65368</ispartof><rights>Copyright © 2024, Yadav et al.</rights><rights>Copyright © 2024, Yadav et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c244t-58f2319b1e7445bdc71e089154d4200c3ddcc56b547d8a1862f43c86e933da823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39184745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yadav, Rohitash</creatorcontrib><creatorcontrib>Tiwari, Chakrmani</creatorcontrib><creatorcontrib>Kumar, Vinod</creatorcontrib><creatorcontrib>Pandey, Avaneesh</creatorcontrib><creatorcontrib>Kondel, Ritika</creatorcontrib><creatorcontrib>Shafiq, Nushrat</creatorcontrib><title>Sustained Delivery of Rifampicin Nanoformulation Administration Intravitreally Into Rabbit Eyes for Ocular Tuberculosis</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Diagnosis and treatment of ocular tuberculosis is very challenging. It poses a significant and potential management dilemma after diagnosis as a primary, active, or secondary infection. The higher amounts of orally administered antitubercular drugs are needed to achieve the therapeutic concentration in the eye, which may lead to a higher risk of side effects. However, the intravitreal administration of drugs is not practiced because of the frequent administration of the injections.
This study was carried out to develop, optimize, and characterize rifampicin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles to make them sustained release followed by the direct administration of plain rifampicin and rifampicin nano-formulations in the vitreous of rabbit eyes. Both groups were comparatively assessed for the sustained delivery of the two preparations in the vitreous and their systemic toxicity.
The characteristics of rifampicin-loaded nanoparticles were 786 nm in size with narrow size distribution along with a zeta potential of -12 mV. The drug encapsulation efficiency and loading capacity were 67.68% w/w and 42.28% w/w, respectively. The four New Zealand white rabbits were divided into two groups and given plain rifampicin (50µl volume) and PLGA nanoformulations of rifampicin (50µl volume) in each eye. In vivo, rifampicin-loaded PLGA nanoparticles produced sustained release of rifampicin for a week, even obtaining the 0.51 µg/ml levels on the seventh day in vitreous against negligible levels after one day for free rifampicin. The Cmax levels for free Rifampicin and Rifampicin nanoparticles were 0.44 µg/ml and 1.86 µg/ml, respectively.
In this experimental proof-of-concept study, we have found that rifampicin-loaded PLGA nanoparticles released rifampicin in a sustained manner for up to seven days compared to free drugs only for one day into the vitreous. The intravitreal-administered drug did not reach systemic circulation.</description><subject>Animals</subject><subject>Chromatography</subject><subject>Drug delivery systems</subject><subject>Drug dosages</subject><subject>Ketamine</subject><subject>Nanoparticles</subject><subject>Particle size</subject><subject>Plasma</subject><subject>Rabbits</subject><subject>Tuberculosis</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkUtLAzEUhYMoVrQ71xJw48LWPCfJUnyDKPhYD5kkA5GZSU0mSv-9qa0iru65l-8cLhwADjGaC8HVmcnR5TSvOK3kFtgjuJIziSXb_qMnYJrSG0III0GQQLtgQlW5C8b3wOdzTqP2g7Pw0nX-w8UlDC188q3uF974AT7oIbQh9rnTow8DPLe9H3wa43q9G4r68GN0uuuWqzXAJ900foRXS5dgscJHU8wRvuTGxSJD8ukA7LS6S266mfvg9frq5eJ2dv94c3dxfj8zhLFxxmVLKFYNdoIx3lgjsENSYc4sIwgZaq0xvGo4E1ZqLCvSMmpk5RSlVktC98HJOncRw3t2aax7n4zrOj24kFNNkRIlTWFR0ON_6FvIcSjfrShFOCdYFep0TZkYUoqurRfR9zoua4zqVSf1upP6u5OCH21Cc9M7-wv_NEC_AMeficA</recordid><startdate>20240725</startdate><enddate>20240725</enddate><creator>Yadav, Rohitash</creator><creator>Tiwari, Chakrmani</creator><creator>Kumar, Vinod</creator><creator>Pandey, Avaneesh</creator><creator>Kondel, Ritika</creator><creator>Shafiq, Nushrat</creator><general>Cureus Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20240725</creationdate><title>Sustained Delivery of Rifampicin Nanoformulation Administration Intravitreally Into Rabbit Eyes for Ocular Tuberculosis</title><author>Yadav, Rohitash ; Tiwari, Chakrmani ; Kumar, Vinod ; Pandey, Avaneesh ; Kondel, Ritika ; Shafiq, Nushrat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c244t-58f2319b1e7445bdc71e089154d4200c3ddcc56b547d8a1862f43c86e933da823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Chromatography</topic><topic>Drug delivery systems</topic><topic>Drug dosages</topic><topic>Ketamine</topic><topic>Nanoparticles</topic><topic>Particle size</topic><topic>Plasma</topic><topic>Rabbits</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yadav, Rohitash</creatorcontrib><creatorcontrib>Tiwari, Chakrmani</creatorcontrib><creatorcontrib>Kumar, Vinod</creatorcontrib><creatorcontrib>Pandey, Avaneesh</creatorcontrib><creatorcontrib>Kondel, Ritika</creatorcontrib><creatorcontrib>Shafiq, Nushrat</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yadav, Rohitash</au><au>Tiwari, Chakrmani</au><au>Kumar, Vinod</au><au>Pandey, Avaneesh</au><au>Kondel, Ritika</au><au>Shafiq, Nushrat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained Delivery of Rifampicin Nanoformulation Administration Intravitreally Into Rabbit Eyes for Ocular Tuberculosis</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-07-25</date><risdate>2024</risdate><volume>16</volume><issue>7</issue><spage>e65368</spage><pages>e65368-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Diagnosis and treatment of ocular tuberculosis is very challenging. It poses a significant and potential management dilemma after diagnosis as a primary, active, or secondary infection. The higher amounts of orally administered antitubercular drugs are needed to achieve the therapeutic concentration in the eye, which may lead to a higher risk of side effects. However, the intravitreal administration of drugs is not practiced because of the frequent administration of the injections.
This study was carried out to develop, optimize, and characterize rifampicin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles to make them sustained release followed by the direct administration of plain rifampicin and rifampicin nano-formulations in the vitreous of rabbit eyes. Both groups were comparatively assessed for the sustained delivery of the two preparations in the vitreous and their systemic toxicity.
The characteristics of rifampicin-loaded nanoparticles were 786 nm in size with narrow size distribution along with a zeta potential of -12 mV. The drug encapsulation efficiency and loading capacity were 67.68% w/w and 42.28% w/w, respectively. The four New Zealand white rabbits were divided into two groups and given plain rifampicin (50µl volume) and PLGA nanoformulations of rifampicin (50µl volume) in each eye. In vivo, rifampicin-loaded PLGA nanoparticles produced sustained release of rifampicin for a week, even obtaining the 0.51 µg/ml levels on the seventh day in vitreous against negligible levels after one day for free rifampicin. The Cmax levels for free Rifampicin and Rifampicin nanoparticles were 0.44 µg/ml and 1.86 µg/ml, respectively.
In this experimental proof-of-concept study, we have found that rifampicin-loaded PLGA nanoparticles released rifampicin in a sustained manner for up to seven days compared to free drugs only for one day into the vitreous. The intravitreal-administered drug did not reach systemic circulation.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>39184745</pmid><doi>10.7759/cureus.65368</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-8184 |
ispartof | Curēus (Palo Alto, CA), 2024-07, Vol.16 (7), p.e65368 |
issn | 2168-8184 2168-8184 |
language | eng |
recordid | cdi_proquest_miscellaneous_3097154917 |
source | PubMed Central; PubMed Central Open Access |
subjects | Animals Chromatography Drug delivery systems Drug dosages Ketamine Nanoparticles Particle size Plasma Rabbits Tuberculosis |
title | Sustained Delivery of Rifampicin Nanoformulation Administration Intravitreally Into Rabbit Eyes for Ocular Tuberculosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A33%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20Delivery%20of%20Rifampicin%20Nanoformulation%20Administration%20Intravitreally%20Into%20Rabbit%20Eyes%20for%20Ocular%20Tuberculosis&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Yadav,%20Rohitash&rft.date=2024-07-25&rft.volume=16&rft.issue=7&rft.spage=e65368&rft.pages=e65368-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.65368&rft_dat=%3Cproquest_cross%3E3099255219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3099255219&rft_id=info:pmid/39184745&rfr_iscdi=true |